Literature DB >> 34923034

Online adaptive radiotherapy potentially reduces toxicity for high-risk prostate cancer treatment.

Rasmus Lübeck Christiansen1, Lars Dysager2, Christian Rønn Hansen3, Henrik Robenhagen Jensen4, Tine Schytte5, Christina Junker Nyborg2, Anders Smedegaard Bertelsen4, Søren Nielsen Agergaard4, Faisal Mahmood3, Steinbjørn Hansen2, Olfred Hansen5, Carsten Brink3, Uffe Bernchou3.   

Abstract

BACKGROUND AND
PURPOSE: With daily, MR-guided online adapted radiotherapy (MRgART) it may be possible to reduce the PTV in pelvic RT. This study investigated the potential reduction in normal tissue complication probability (NTCP) of MRgART compared to standard radiotherapy for high-risk prostate cancer.
MATERIALS AND METHODS: Twenty patients treated with 78 Gy to the prostate and 56 Gy to elective pelvic lymph nodes were included. VMAT plans were generated with standard clinical PTV margins. Additionally to the planning MR, patients had three MRI scans during treatment to simulate an MRgART. A reference plan with PTV margins determined for MRgART was created per patient and adapted to each of the following MRs. Adapted plans were warped to the planning MR for dose accumulation. The standard plan was rigidly registered to each adaptation MR before it was warped to the planning MR for dose accumulation. Dosimetric impact was compared by DVH analysis and potential clinical effects were assessed by NTCP modeling.
RESULTS: MRgART yielded statistically significant lower doses for the bladder wall, rectum and peritoneal cavity, compared to the standard RT, which translated into reduced median risks of urine incontinence (ΔNTCP 2.8%), urine voiding pain (ΔNTCP 2.8%) and acute gastrointestinal toxicity (ΔNTCP 17.4%). Mean population accumulated doses were as good or better for all investigated OAR when planned for MRgART as standard RT.
CONCLUSION: Online adapted radiotherapy may reduce the dose to organs at risk in high-risk prostate cancer patients, due to reduced PTV margins. This potentially translates to significant reductions in the risks of acute and late adverse effects.
Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adaptive radiotherapy; MR-guided radiotherapy; NTCP-modelling; PTV margin; Prostate cancer

Mesh:

Year:  2021        PMID: 34923034     DOI: 10.1016/j.radonc.2021.12.013

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  3 in total

1.  Assessment of a Therapeutic X-ray Radiation Dose Measurement System Based on a Flexible Copper Indium Gallium Selenide Solar Cell.

Authors:  Dong-Seok Shin; Tae-Ho Kim; Jeong-Eun Rah; Dohyeon Kim; Hye Jeong Yang; Se Byeong Lee; Young Kyung Lim; Jonghwi Jeong; Haksoo Kim; Dongho Shin; Jaeman Son
Journal:  Sensors (Basel)       Date:  2022-08-04       Impact factor: 3.847

2.  A Prospective Study of Stereotactic Body Radiotherapy (SBRT) with Concomitant Whole-Pelvic Radiotherapy (WPRT) for High-Risk Localized Prostate Cancer Patients Using 1.5 Tesla Magnetic Resonance Guidance: The Preliminary Clinical Outcome.

Authors:  Darren M C Poon; Jing Yuan; Bin Yang; Oi-Lei Wong; Sin-Ting Chiu; George Chiu; Kin-Yin Cheung; Siu-Ki Yu; Raymond W H Yung
Journal:  Cancers (Basel)       Date:  2022-07-18       Impact factor: 6.575

3.  Synthetic CT generation for MRI-guided adaptive radiotherapy in prostate cancer.

Authors:  Shu-Hui Hsu; Zhaohui Han; Jonathan E Leeman; Yue-Houng Hu; Raymond H Mak; Atchar Sudhyadhom
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.